These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
624 related articles for article (PubMed ID: 10850310)
21. B cell non-Hodgkin's lymphoma: rituximab safety experience. Mohrbacher A Arthritis Res Ther; 2005; 7 Suppl 3(Suppl 3):S19-25. PubMed ID: 15960818 [TBL] [Abstract][Full Text] [Related]
22. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma. Zhang H; Song L; Ye H; Hu L; Liang W; Liu D Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075 [TBL] [Abstract][Full Text] [Related]
23. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma]. Hao LC; Zhang LZ Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396 [No Abstract] [Full Text] [Related]
24. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Traullé C; Coiffier BB Future Oncol; 2005 Jun; 1(3):297-306. PubMed ID: 16556002 [TBL] [Abstract][Full Text] [Related]
25. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. Liu C; DeNardo G; Tobin E; DeNardo S Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447 [TBL] [Abstract][Full Text] [Related]
27. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma. Bauduer F Br J Haematol; 2001 Mar; 112(4):1085-6. PubMed ID: 11324638 [No Abstract] [Full Text] [Related]
28. Rituximab: ongoing and future clinical development. Grillo-López AJ; Hedrick E; Rashford M; Benyunes M Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397 [TBL] [Abstract][Full Text] [Related]
29. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Shaw T; Quan J; Totoritis MC Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151 [No Abstract] [Full Text] [Related]
30. Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma? Leonard JP Clin Adv Hematol Oncol; 2012 Aug; 10(8):540-2. PubMed ID: 23073054 [No Abstract] [Full Text] [Related]
31. [Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma]. Mihaljević B; Janković S; Jaković L; Jovanović MP; Andelić B; Milosević V; Sretenović A; Virijević M; Petrovic M Vojnosanit Pregl; 2008 Mar; 65(3):229-33. PubMed ID: 18494271 [No Abstract] [Full Text] [Related]
32. Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma. Singh F; Weinberg JM Cutis; 2005 Sep; 76(3):186-8. PubMed ID: 16268262 [TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622 [TBL] [Abstract][Full Text] [Related]